Nilotinib-d3 is a labeled analogue of Nilotinib which functions as a Bcr-Abl tyrosine kinase antagonist. Studies suggest that Nilotinib-d3 inhibits proliferation, migration and actin filament formation in HSCs. In addition, Nilotinib-d3 can cause apoptosis in HSCs via reducing the expression of bcl-2 and increasing the expression p53, cleavage of PARP, along with an increased expression of PPARγ and TRAIL-R. Nilotinib-d3 strongly inhibits the phosphorylation of ERK and Akt1 via suppressing PDGF and TGFβ. Alternatively, Nilotinib-d3 shows significant efficacy towards chronic myeloid leukemia in chronic, accelerated, and blastic phases. Nilotinib-d3 is far more effective than imatinib and dasatinib at inhibiting rhodamine 123 and Hoechst 33342 efflux in human hematopoietic stem cells.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.